Lexicon presents post hoc analysis of data from SCORED trial

Lexicon Pharmaceuticals announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA use in heart failure and major adverse cardiovascular events related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events. The goal of the analysis was to evaluate the time to clinical benefit for HF and MACE related outcomes in patients at high risk for cardiovascular events and treated with sotagliflozin. For total cardiovascular deaths, hospitalizations for HF, or urgent visits for HF, the primary endpoint of the trial, the relative risk reduction observed in patients treated with sotagliflozin vs. placebo was 26%. A statistically significant sustained reduction in the primary endpoint was seen at 95 days after randomization. For MACE, a predefined secondary endpoint of the trial, the relative risk reduction observed in patients treated with sotagliflozin vs. placebo was 23% . A statistically significant sustained reduction in MACE was seen at 94 days after randomization. During the Scientific Sessions, researchers also presented data from Lexicon-supported studies relating to INPEFA’s mechanism of action and pharmacoeconomic analyses of INPEFA use, as well as real world evidence for patients hospitalized with heart failure.